Key questions, he suggested, are, What is the role of a second TKI after progression with a first TKI, and does it matter whether patients benefited from the first TKI when choosing second-line therapy? "But more importantly, [with] my apologies to industry, Do we need more TKIs or mTOR inhibitors, or do we want a new target in this disease?" asked Dr. Redman.
Pfizer sponsored the AXIS trial. Dr. Rini disclosed an advisory role with and research funding from Pfizer. Dr. Cella disclosed advisory roles with AVEO, Bayer, and Pfizer, and research funding from AVEO, Bayer, Novartis, and Pfizer. Dr. Redman disclosed stock ownership in Novartis.